UPDATE: Phase 3 Data Support a Novel Mechanism for Male Hair Loss: Spokane Dermatologist Dr. Wm. Philip Werschler on the Significance of the Clascoterone Results

Cosmo Announces SIX Ticker Symbol Change to "CMHC"

Voting Results of Cosmo's 2026 AGM

Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant

Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark

Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany

Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026

Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance

Largest Real-World Study of the GI Genius(TM) Intelligent Endoscopy System Demonstrates Improved Adenoma Detection in Routine Clinical Practice

Cosmo Announces Positive Phase 2 Study of Rifamycin 1% Topically Acting Gel, Meeting the Primary Endpoint in Distal Ulcerative Colitis and Ulcerative Proctitis